Specifically, this finding was consistent across the subgroups of patients with type II diabetes mellitus and hypertension, indicating that PCSK9 inhibitors serve as a protective factor against CA-AKI. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.